RECRUITING

Transtibial Osseointegration

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Purpose: Aim 1: Quantify soft tissue complications and infections of service members with transtibial amputations treated with OPRA OI and compare them to transfemoral OI service members. Aim 2: Compare the validated domains, such as functional, quality of life and pain scores, from the preoperative baseline to follow-up visits to determine if persons with transtibial amputations treated with OPRA osseointegrated prostheses demonstrate statistically significant and clinically relevant improvements. Aim 3: Compare physical performance measures preoperatively to follow-up visits for persons with transtibial amputations treated with OPRA osseointegrated prostheses to quantify statistically significant and clinically relevant improvements. Aim 4: Quantify the biomechanical loading and bone quality changes that are directly associated with patient reported outcomes for persons with transtibial amputations treated with OPRA osseointegration. Aim 5: Compare outcome measures between persons with traditional socket prostheses (patients as self-controls) and OPRA OI devices as well as a comparison between persons with transtibial OI and transfemoral OI. Subject Population: Male and female military health care beneficiaries age 22 to 65 years old presenting with a Transtibial limb loss. Study Design: This is a 4-year, prospective cohort FDA pivotal study involving off-label use of the OPRA OI implant in persons with transtibial amputation. Procedures: SURGICAL PROCEDURES: Surgery Stage I: The distal part of the tibia is exposed, preferably using existing incisions, to produce an appropriate fasciocutaneous flap. By the use of fluoroscopy and guiding devices the correct position of the fixture in the medullary canal is found. The canal is reamed step by step to a proper diameter to facilitate insertion of the implant. If the bone quality is poor, as determined by the operating surgeon, autologous bone graft from the iliac crest and/or the medullary canal is used. The fixture is then implanted into the intramedullary canal. Careful surgical technique is essential not to damage the tissue and to achieve osseointegration. A central screw, healing cylinder, and healing bolt are inserted. A myodesis is performed, and the wound is closed using suture. The sutures are removed 2-3 weeks postoperatively. When the skin is completely healed the Patient's conventional socket prosthesis could, in some instances, be used. Surgery Stage II (3-5 months after Stage I): The tibia is exposed via the incision from the Stage I-Surgery. The healing cylinder is removed and the tissues are trimmed in a way that the distal end of the bone protrudes a few millimeters. The skin will be attached directly to it. The endosteal canal is reamed to facilitate placement of the abutment. The skin in the abutment area is then trimmed to a diameter equal to the protruding end of the tibia. This is done to remove the subcutaneous fat and facilitate healing of the dermal layer to the distal end of the bone. The subcutaneous tissue is affixed to the periosteum using absorbable suture to prevent skin movement. A 8mm punch biopsy tool is used to create a circular hole in the skin precisely over the residual tibial canal. The remaining portion of the fasciocutaneous flap is sutured into position. A bolster dressing is placed and routine postoperative wound care is performed by daily dressing changes. Sutures are removed 2-3 weeks postoperatively. CLINICAL PROCEDURES A pre-study visit will be conducted up to 6 months prior to Surgery Stage I. Postoperative visits will occur 2-3 weeks after each surgery. Additional follow-up visits will occur 6, 12, 24, 36, 48 and 60 months post-Surgery Stage II. It is standard of care to follow patients postoperatively from time to time to ensure the wound(s) is /are healing, surveil for complications, and ensure rehabilitation is progressing. That said, the sole reason for engaging in the Clinical Follow-Up Procedures is for the purpose of conducting research under this particular protocol. Additional visits may occur including x-rays at the discretion of the clinical investigator in order to monitor the participants medical status/bone healing. RESEARCH PROCEDURES Timepoints: Baseline, Post-Op Stage II, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months The patients will be assessed before and after the surgery regularly. Both performance and safety data will be recorded on specially designed electronic Case Report Forms (eCRFs). Clinical and radiological assessments are performed preoperatively (in connection with the surgical procedures.

Official Title

Transtibial Osseointegration Surgery Study (TOSS)

Quick Facts

Study Start:2025-05-20
Study Completion:2030-04-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06636136

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:22 Years to 65 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Diagnosis of a transtibial amputation age 22-65.
  2. * The OPRA™ Implant System is indicated for patients who have transtibial amputation due to trauma or cancer and who have or are anticipated to have rehabilitation problems with, or cannot use, a conventional socket prosthesis. The OPRA™ Implant System is intended for skeletally mature patients.
  3. * The patient failed to receive benefit from socket prostheses or is expected to not tolerate socket use due to problems such as:
  4. * Recurrent skin infections and ulcerations in the socket contact area
  5. * Pain
  6. * A short stump preventing the use of socket prosthesis
  7. * Volume fluctuation in the stump
  8. * Soft tissue scarring
  9. * Extensive area of skin grafting
  10. * Socket retention problems due to excessive perspiration
  11. * Restricted mobility
  12. * Eligible to receive care at Military Treatment Facility
  13. * DEERS-eligible
  1. * The patient's skeletal growth is not complete. Completed skeletal growth is defined through the finding of generally closed epiphyseal zones on X-ray.
  2. * The patient has atypical skeletal anatomy which may affect treatment with OPRA™.
  3. * Examples of atypical skeletal anatomy.
  4. * Skeletal dimensions outside defined interval.
  5. * Development anomalies.
  6. * Conditions which are not amenable to device insertion such as deformities, fracture, infection.
  7. * The patient would have less than 2 mm of remaining cortex bone available around the implant, if implanted.
  8. * Osteoporosis.
  9. * The patient is older than 65 years and younger than 22 years.
  10. * BMI over 35.
  11. * Do not treat patients with the following concurrent diseases:
  12. * Severe peripheral vascular disease.
  13. * Diabetic mellitus with complications.
  14. * Neuropathy or neuropathic disease.
  15. * Active infection or dormant bacteria.
  16. * Metabolic bone disease and/or metastatic lesions in the residual tibia.
  17. * Pregnancy before the surgery female patients will take a pregnancy test) Note: Patients who become pregnant, after surgery stage I, surgery stage II will be delayed until safe to do so by their doctor. The patient will remain in the study, unless they would like to withdrawal.
  18. * The patient is not expected to be able to comply with treatment and follow up requirements.
  19. * Participants unable to sign their own consent (No legally authorized representatives may provide consent)

Contacts and Locations

Study Contact

Emma M Stewart
CONTACT
202-549-3229
emma.l.stewart4.ctr@health.mil
Toby L Perkins
CONTACT
240-308-0548
toby.l.perkins.ctr@health.mil

Principal Investigator

Ashley Bee Anderson, MD
PRINCIPAL_INVESTIGATOR
Walter Reed National Military Medical Center

Study Locations (Sites)

Orhopaedic Surgery Service, Walter Reed National Military Medical Center,
Bethesda, Maryland, 20889
United States
Department of Orthopaedic Surgery and Department of Anesthesiology & Critical Care Penn Medicine University City
Philadelphia, Pennsylvania, 19104
United States

Collaborators and Investigators

Sponsor: Walter Reed National Military Medical Center

  • Ashley Bee Anderson, MD, PRINCIPAL_INVESTIGATOR, Walter Reed National Military Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-05-20
Study Completion Date2030-04-30

Study Record Updates

Study Start Date2025-05-20
Study Completion Date2030-04-30

Terms related to this study

Keywords Provided by Researchers

  • Transtibial
  • Osseointegration

Additional Relevant MeSH Terms

  • Amputation; Traumatic, Leg, Lower